OABIW — OmniAb, Inc.

Summary of OmniAb, Inc. (OABIW) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by increased milestone revenue.
• Full Year 2025 Revenue: $18.7 million, compared to $26.4 million in 2024, attributed to decreased license and milestone revenue.
• Operating Expenses: Decreased to $24.1 million in Q4 2025 from $26.7 million in Q4 2024, with a full-year total of $87.6 million, down from $100.9 million in 2024.
• Net Loss: Q4 net loss of $14.2 million ($0.11 per share) compared to a loss of $13.1 million ($0.12 per share) in Q4 2024. Full-year net loss was $64.8 million ($0.57 per share) versus $62 million ($0.61 per share) in 2024.
• Cash Position: Ended 2025 with $54 million in cash and equivalents, expected to decrease to $30-$35 million by the end of 2026.

2. Strategic Updates and Business Highlights

• Partnerships: OmniAb ended 2025 with 107 partners and 407 active programs, reflecting strong growth in partner additions and program execution.
• New Technologies: Launched OmniUltra, a transgenic chicken platform for antibody development, and xPloration, a high-throughput single B-cell screening platform, both expected to drive future growth.
• Program Advancements: 25 programs advanced through various development stages in 2025, including one reaching the registration stage, indicating strong performance of OmniAb-enabled therapeutics.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $25 million and $30 million, indicating a recovery from 2025 levels.
• Operating Expenses: Projected to be $80 million to $85 million, with cash operating expenses expected at $50 million to $55 million.
• Long-term Outlook: The company anticipates a transition from milestone-driven to more royalty-driven revenue, with over $3 billion in contracted milestones and an average royalty rate of 3.4%.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Significant drop in both quarterly and annual revenue compared to the previous year, primarily due to lower license and milestone revenues.
• Net Loss: Continued net losses raise concerns about profitability and cash flow sustainability.
• Market Conditions: Potential headwinds from market fundraising activities and economic conditions affecting partner spending and program initiation.

5. Notable Q&A Insights

• Program Growth: Management expressed confidence in new program growth for 2026, driven by recent technology launches and strong partner engagement.
• xPloration Demand: Positive reception with two instruments deployed by year-end 2025, indicating strong interest from high-tier partners.
• Cash Flow Breakeven: While management did not provide a specific timeline, they indicated confidence in reaching cash flow positivity as the portfolio matures.
• Royalty Structure: Most deals are based on flat royalties, with potential for higher rates on new technologies, reflecting the value of innovation in negotiations.

Overall, while OmniAb has shown promising developments in partnerships and technology advancements, it faces challenges with declining revenues and ongoing net losses, necessitating careful management of expenses and strategic growth initiatives moving forward.